COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,844 Articles (22,553 medRxiv, 8,291 bioRxiv)

Most recent first Previous |  Page 2158: Articles 21571-21580  | Next

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus
Chen, J., Dai, L., Barrett, L., Post, S. R., Qin, Z.
10.1101/2020.10.02.324228 — Posted: 2020-10-02
Transmission of SARS-COV-2 from China to Europe and West Africa: a detailed phylogenetic analysis.
Wruck, W., Adjaye, J.
10.1101/2020.10.02.323519 — Posted: 2020-10-02
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
Guo, Y., Kawaguchi, A., Takeshita, M., Sekiya, T., Hirohama, M., Yamashita, A., the Keio Donner Project, , Siomi, H., Murano, K.
10.1101/2020.10.01.323220 — Posted: 2020-10-02
Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19
Hennrich, A. A., Banda, D. H., Oberhuber, M., Schopf, A., Pfaffinger, V., Wittwer, K., Sawatsky, B., Riedel, C., Pfaller, C. K., Conzelmann, K.-K.
10.1101/2020.10.02.324046 — Posted: 2020-10-02
SARS-CoV-2 infected cells present HLA-I peptides from canonical and out-of-frame ORFs
Weingarten-Gabbay, S., Klaeger, S., Sarkizova, S., Pearlman, L. R., Chen, D.-Y., Bauer, M. R., Taylor, H. B., Conway, H. L., Tomkins-Tinch, C. H., Finkel, Y., Nachshon, A., Gentili, M., Rivera, K. D., Keskin, D. B., Rice, C. M., Clauser, K. R., Hacohen, N., Carr, S. A., Abelin, J. G., Saeed, M., Sabeti, P. C.
10.1101/2020.10.02.324145 — Posted: 2020-10-02
A Multiscale Coarse-grained Model of the SARS-CoV-2 Virion
Yu, A., Pak, A. J., He, P., Monje-Galvan, V., Casalino, L., Gaieb, Z., Dommer, A. C., Amaro, R. E., Voth, G. A.
10.1101/2020.10.02.323915 — Posted: 2020-10-02
A One-Minute Blood Test to Monitor Immune Responses in COVID-19 Patients and Predict Clinical Risks of Developing Moderate to Severe Symptoms
Deb, C., Salinas, A. N., Middleton, A., Kern, K., Penoyer, D., Borsadia, R., Hunley, C., Mehta, V., Irastorza, L., Mehta, D. I., Zheng, T., HUO, Q.
10.1101/2020.09.30.20203844 — Posted: 2020-10-02
Tracing and testing the COVID-19 contact chain: cost-benefit tradeoffs
Kim, J., Chen, X., Bidokhti, S. S., Sarkar, S.
10.1101/2020.10.01.20205047 — Posted: 2020-10-02
Quantifying the dynamics of COVID-19 burden and impact of interventions in Java, Indonesia
Djaafara, B. A., Whittaker, C., Watson, O. J., Verity, R., Brazeau, N. F., Widyastuti, W., Oktavia, D., Adrian, V., Salama, N., Bhatia, S., Nouvellet, P., Sherrard-Smith, E., Churcher, T. S., Surendra, H., Lina, R. N., Ekawati, L. L., Lestari, K. D., Andrianto, A., Thwaites, G., Baird, J. K., Ghani, A. C., Elyazar, I. R., Walker, P. G.
10.1101/2020.10.02.20198663 — Posted: 2020-10-02
The SARS-CoV-2 effective reproduction rate has a high correlation with a contact index derived from large-scale individual location data using GPS-enabled mobile phones in Germany
Ruediger, S., Konigorski, S., Edelman, J., Zernick, D., Lippert, C., Thieme, A. H.
10.1101/2020.10.02.20188136 — Posted: 2020-10-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).